Association of Combined Estrogen–Progestogen and Progestogen-Only Contraceptives with the Development of Cancer

Abstract

Combined estrogen–progestogen contraceptives (oral contraceptives or OCs) and progestogen-only contraceptives (POCs) are synthetic steroids that bind to steroid hormone receptors, which are widespread throughout the body. They have a profound effect on cellular physiology. Combined OCs have been classified by the International Agency for Research on Cancer (IARC) as Group 1 carcinogens, but their findings have not been updated recently. In order to update the information and better understand the impact that OCs and POCs have on the risk of development of cancers, a comprehensive literature search was undertaken, focusing on more recently published papers. In agreement with the IARC, the recent literature confirms an increased risk of breast cancer and cervical cancer with the use of OCs. The recent literature also confirms the IARC conclusion that OCs decrease the risk of ovarian and endometrial cancers. However, there is little support from recent studies for the IARC conclusion that OCs decrease the risk of colorectal cancer or increase the risk of liver cancer. For liver cancer, this may be due to the recent studies having been performed in areas where hepatitis is endemic. In one large observational study, POCs also appear to increase the overall risk of developing cancer. OCs and POCs appear to increase the overall risk of cancer when carefully performed studies with the least intrinsic bias are considered.

Summary:

OCs have been classified as cancer-causing agents, especially leading to increases in breast cancer and cervical cancer. A review of the recent scientific literature was performed to see whether this still appears to be the case. The recent literature supports the cancer-causing role of OCs especially for breast cancer and cervical cancer. Studies also indicate that progesterone-only contraceptives (such as implants and vaginal rings) also can cause cancer. This is especially true for breast cancer and cervical cancer.

Keywords

Breast cancer Cancer Cervical cancer Colorectal cancer Contraception Contraceptive Endometrial cancer Estrogen Ovarian cancer Progestogen

Get full access to this article

View all access options for this article.

References

Altman

Douglas G.

1991. Practical Statistics for Medical Research. London, UK: Chapman and Hall.

Amadou

Fabre

Torres-Mejía

Ortega-Olvera

Angeles-Llerenas

McKenzie

Biessy

Hainaut

Romieu

. 2013. “Hormonal Therapy and Risk of Breast Cancer in Mexican Women.” PLoS One 8:e79695.

2015. “Oral Contraceptives Use and Liver Cancer Risk: A Dose-response Meta-analysis of Observational Studies.” Medicine (Baltimore) 94:e1619.

Antoniou

A. C.

Rookus

Andrieu

Brohet

Chang-Claude

Peock

Cook

. 2009. “Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study.” Cancer Epidemiology, Biomarkers & Prevention 18, no. 2: 601–10. doi: 10.1158/1055-9965.EPI-08-0546.

Arab

Khayamzadeh

Tehranian

Tabatabaeefar

Hosseini

Anbiaee

Golfam

Akbari

M. E.

. 2010. “Incidence Rate of Ovarian Cancer in Iran in Comparison with Developed Countries.” Indian Journal of Cancer 47, no. 3: 322–27. doi: 10.4103/0019-509X.64721.

Baik

C. S.

Strauss

G. M.

Speizer

F. E.

Feskanich

. 2010. “Reproductive Factors, Hormone Use, and Risk for Lung Cancer in Postmenopausal Women, the Nurses’ Health Study.” Cancer Epidemiology, Biomarkers & Prevention 19:2525–33.

Beaber

E. F.

Buist

D. S.

Barlow

W. E.

Malone

K. E.

Reed

S. D.

C. I.

. 2014. “Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age.” Cancer Research 74:4078–89.

Beaber

E. F.

Malone

K. E.

Tang

M. T.

Barlow

W. E.

Porter

P. L.

Daling

J. R.

C. I.

. 2014. “Oral Contraceptives and Breast Cancer Risk Overall and by Molecular Subtype among Young Women.” Cancer Epidemiology, Biomarkers & Prevention 23:755–64.

Beji

N. K.

Reis

. 2007. “Risk Factors for Breast Cancer in Turkish Women: A Hospital-based Case-control Study.” European Journal of Cancer Care 16:178–84.

10.

Bethea

T. N.

Rosenberg

Hong

C. C.

Troester

M. A.

Lunetta

K. L.

Bandera

E. V.

Schedin

. 2015. “A Case-control Analysis of Oral Contraceptive Use and Breast Cancer Subtypes in the African American Breast Cancer Epidemiology and Risk Consortium.” Breast Cancer Research 17:22.

11.

Birch-Johansen

Jensen

Olesen

A. B.

Christensen

Tjønneland

Kjær

S. K.

. 2012. “Does Hormone Replacement Therapy and Use of Oral Contraceptives Increase the Risk of Non-melanoma Skin Cancer?” Cancer Causes & Control 23:379–88.

12.

Blokhuis

M. M.

Pietersen

G. E.

Goldberg

P. A.

Algar

Van der Merwe

Mbatani

Vorster

A. A.

Ramesar

R. S.

. 2010. “Lynch Syndrome: The Influence of Environmental Factors on Extracolonic Cancer Risk in hMLH1 c.C1528T Mutation Carriers and Their Mutation-negative Sisters.” Familial Cancer 9:357–63.

13.

Bodmer

Becker

Meier

Jick

S. S.

Meier

C. R.

. 2011. “Use of Metformin and the Risk of Ovarian Cancer: A Case-control Analysis.” Gynecologic Oncology 123, no. 2: 200–204. doi: 10.1016/j.ygyno.2011.06.038.

14.

Bosetti

Bravi

Negri

La Vecchia

. 2009. “Oral Contraceptives and Colorectal Cancer Risk: A Systematic Review and Meta-analysis.” Human Reproduction Update 15:489–98.

15.

Braem

M. G.

Onland-Moret

N. C.

van den Brandt

P. A.

Goldbohm

R. A.

Peeters

P. H.

Kruitwagen

R. F.

Schouten

L. J.

. 2010. “Reproductive and Hormonal Factors in Association with Ovarian Cancer in the Netherlands Cohort Study.” American Journal of Epidemiology 172, no. 10: 1181–89. doi: 10.1093/aje/kwq264.

16.

Braganza

M. Z.

de González

A. B.

Schonfeld

S. J.

Wentzensen

Brenner

A. V.

Kitahara

C. M.

. 2014. “Benign Breast and Gynecologic Conditions, Reproductive and Hormonal Factors, and Risk of Thyroid Cancer.” Cancer Prevention Research (Philadelphia) 7:418–25.

17.

Brändstedt

Wangefjord

Nodin

Eberhard

Jirström

Manjer

. 2014. “Associations of Hormone Replacement Therapy and Oral Contraceptives with Risk of Colorectal Cancer Defined by Clinicopathological Factors, Beta-catenin Alterations, Expression of Cyclin D1, p53, and Microsatellite-instability.” BMC Cancer 14:371.

18.

Brohet

R. M.

Goldgar

D. E.

Easton

D. F.

Antoniou

A. C.

Andrieu

Chang-Claude

Peock

. 2007. “Oral Contraceptives and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study: A Report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.” Journal of Clinical Oncology 25:3831–36.

19.

Camargo

M. C.

Goto

Zabaleta

Morgan

D. R.

Correa

Rabkin

C. S.

. 2012. “Sex Hormones, Hormonal Interventions, and Gastric Cancer Risk: A Meta-analysis.” Cancer Epidemiology, Biomarkers & Prevention 21:20–38.

20.

Campbell

P. T.

Newcomb

Gallinger

Cotterchio

McLaughlin

J. R.

. 2007. “Exogenous Hormones and Colorectal Cancer Risk in Canada: Associations Stratified by Clinically Defined Familial Risk of Cancer.” Cancer Causes & Control 18:723–33.

21.

Cantwell

M. M.

Lacey

J. V.

Jr. Schairer

Schatzkin

Michaud

D. S.

. 2006. “Reproductive Factors, Exogenous Hormone Use and Bladder Cancer Risk in a Prospective Study.” International Journal of Cancer 119:2398–401.

22.

Cao

Wang

Yin

Sun

Quan

. 2015. “Reproductive Factors But Not Hormonal Factors Associated with Thyroid Cancer Risk: A Systematic Review and Meta-analysis.” BioMed Research International 2015:103515.

23.

Centers for Disease Control. 2018. National Survey of Family Growth. https://www.cdc.gov/nchs/nsfg/key_statistics/c.htm#contraception.

24.

Chang

C. K.

Astrakianakis

Thomas

D. B.

Seixas

N. S.

Ray

R. M.

Gao

D. L.

Wernli

K. J.

. 2006. “Occupational Exposures and Risks of Liver Cancer among Shanghai Female Textile Workers—A Case-cohort Study.” International Journal of Epidemiology 35:361–69.

25.

Charlton

B. M.

Zhang

Giovannucci

E. L.

Fuchs

C. S.

Missmer

S. A.

Rosner

. 2015. “Oral Contraceptive Use and Colorectal Cancer in the Nurses’ Health Study I and II.” Cancer Epidemiology, Biomarkers & Prevention 24:1214–21.

26.

Chen

Tan

Ding

Mai

Huang

Luo

. 2016. “WWOX CNV-67048 Functions as a Risk Factor for Epithelial Ovarian Cancer in Chinese Women by Negatively Interacting with Oral Contraceptive Use.” BioMed Research International 2016:6594039. doi: 10.1155/2016/6594039.

27.

Coffey

Beral

Green

Reeves

Barnes

; Million Women Study Collaborators. Collaborators: Abbiss

Abbott

. 2015. “Lifestyle and Reproductive Risk Factors Associated with Anal Cancer in Women Aged Over 50 Years.” British Journal of Cancer 112:1568–74.

28.

Cogliano

Grosse

Baan

Straif

Secretan

El Ghissassi

; WHO International Agency for Research on Cancer 2005. “Carcinogenicity of Combined Oestrogen–progestagen Contraceptives and Menopausal Treatment.” Lancet Oncology 6:552–53.

29.

Collaborative Group on Epidemiological Studies of Ovarian Cancer. 2008. “Ovarian Cancer and Oral Contraceptives: Collaborative Reanalysis of Data from 45 Epidemiological Studies Including 23 257 Women with Ovarian Cancer and 87 303 Controls.” Lancet 371 no. 9609: 303–14. doi:10.1016/S0140-6736(08)60167-1.

30.

Collaborative Group on Epidemiological Studies on Endometrial Cancer. 2015. “Endometrial Cancer and Oral Contraceptives: An Individual Participant Meta-analysis of 27 276 Women with Endometrial Cancer from 36 Epidemiological Studies.” Lancet Oncology 16:1061–70.

31.

Cook

L. S.

Dong

Round

Huang

Magliocco

A. M.

Friedenreich

C. M.

. 2014. “Hormone Contraception before the First Birth and Endometrial Cancer Risk.” Cancer Epidemiology, Biomarkers & Prevention 23:356–61.

32.

Cote

M. L.

Alhajj

Ruterbusch

J. J.

Bernstein

Brinton

L. A.

Blot

W. J.

Chen

. 2015. “Risk Factors for Endometrial Cancer in Black and White Women: A Pooled Analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2).” Lancet Oncology 16:1061–70.

33.

Dashti

S. G.

Chau

Ouakrim

D. A.

Buchanan

D. D.

Clendenning

Young

J. P.

Winship

I. M.

. 2015. “Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome.” Journal of the American Medical Association 14:61–71.

34.

Deeks

J. J.

Higgins

J. P. T.

. 2010. Statistical Algorithms in Review Manager 5. http://ims.cochrane.org/revman/documentation/Statistical-methods-in-RevMan-5.pdf.

35.

Delort

Kwiatkowski

Chalabi

Satih

Bignon

Y. J.

Bernard-Gallon

D. J.

. 2007. “Risk Factors for Early Age at Breast Cancer Onset—The ‘COSA Program’ Population-based Study.” Anticancer Research 27:1087–94.

36.

Dietrich

Demidenko

Schned

Zens

M. S.

Heaney

Karagas

M. R.

. 2011. “Parity, Early Menopause and the Incidence of Bladder Cancer in Women: A Case-control Study and Meta-analysis.” European Journal of Cancer Care 47:592–99.

37.

Dolle

J. M.

Daling

J. R.

White

Brinton

L. A.

Doody

D. R.

Porter

P. L.

Malone

K. E.

. 2009. “Risk Factors for Triple-negative Breast Cancer in Women under the Age of 45 Years.” Cancer Epidemiology, Biomarkers & Prevention 18:1157–66.

38.

Dorjgochoo

Shu

X. O.

H. L.

Qian

H. Z.

Yang

Cai

Gao

Y. T.

Zheng

. 2009. “Use of Oral Contraceptives, Intrauterine Devices and Tubal Sterilization and Cancer Risk in a Large Prospective Study, from 1996 to 2006.” International Journal of Cancer 124:2442–49.

39.

Dossus

Allen

Kaaks

Bakken

Lund

Tjonneland

Olsen

. 2010. “Reproductive Risk Factors and Endometrial Cancer: The European Prospective Investigation into Cancer and Nutrition.” International Journal of Cancer 127:442–51.

40.

Elliott

A. M.

Hannaford

P. C.

. 2006. “Use of Exogenous Hormones by Women and Lung Cancer: Evidence from the Royal College of General Practitioners’ Oral Contraception Study.” Contraception 73:331–35.

41.

Faber

M. T.

Jensen

Frederiksen

Glud

Høgdall

Blaakaer

Kjaer

S. K.

. 2013. “Oral Contraceptive Use and Impact of Cumulative Intake of Estrogen and Progestin on Risk of Ovarian Cancer.” Cancer Causes & Control 24, no. 12: 2197–206. doi: 10.1007/s10552-013-0296-8.

42.

Ferris

J. S.

Daly

M. B.

Buys

S. S.

Genkinger

J. M.

Liao

Terry

M. B.

. 2014. “Oral Contraceptive and Reproductive Risk Factors for Ovarian Cancer within Sisters in the Breast Cancer Family Registry.” British Journal of Cancer 110, no. 4: 1074–80. doi: 10.1038/bjc.2013.803.

43.

Figueiredo

J. C.

Haile

R. W.

Bernstein

Malone

K. E.

Largent

Langholz

Lynch

C. F.

. 2010. “Oral Contraceptives and Postmenopausal Hormones and Risk of Contralateral Breast Cancer among BRCA1 and BRCA2 Mutation Carriers and Noncarriers: The WECARE Study.” Breast Cancer Research and Treatment 120:175–83.

44.

Folger

S. G.

Marchbanks

P. A.

McDonald

J. A.

Bernstein

Ursin

Berlin

J. A.

Daling

J. R.

. 2007. “Risk of Breast Cancer Associated with Short-term Use of Oral Contraceptives.” Cancer Causes & Control 18:189–98.

45.

Fortner

R. T.

Ose

Merritt

M. A.

Schock

Tjønneland

Hansen

Overvad

. 2015. “Reproductive and Hormone-related Risk Factors for Epithelial Ovarian Cancer by Histologic Pathways, Invasiveness and Histologic Subtypes: Results from the EPIC Cohort.” International Journal of Cancer 137, no. 5: 1196–208. doi: 10.1002/ijc.29471.

46.

Freedman

N. D.

Chow

W. H.

Gao

Y. T.

Shu

X. O.

B. T.

Yang

Lubin

J. H.

. 2007. “Menstrual and Reproductive Factors and Gastric Cancer Risk in a Large Prospective Study of Women.” Gut 56:1671–77.

47.

Friebel

T. M.

Domchek

S. M.

Rebbeck

T. R.

. 2014. “Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: Systematic Review and Meta-analysis.” Journal of the National Cancer Institute 106, no. 6: dju091. doi: 10.1093/jnci/dju091.

48.

Frise

Kreiger

Gallinger

Tomlinson

Cotterchio

. 2006. “Menstrual and Reproductive Risk Factors and Risk for Gastric Adenocarcinoma in Women: Findings from the Canadian National Enhanced Cancer Surveillance System.” Annals of Epidemiology 16:908–16.

49.

Gay

G. M.

Lim

J. S.

Chay

W. Y.

Chow

K. Y.

Tan

M. H.

Lim

W. Y.

. 2015. “Reproductive Factors, Adiposity, Breastfeeding and Their Associations with Ovarian Cancer in an Asian Cohort.” Cancer Causes & Control 26, no. 11: 1561–73. doi: 10.1007/s10552-015-0649-6.

50.

Genecards ESR1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=ESR1&keywords=estrogen,receptor.

51.

Genecards ESR2. https://www.genecards.org/cgi-bin/carddisp.pl?gene=ESR2&keywords=estrogen,receptor.

52.

Genecards PGR. https://www.genecards.org/cgi-bin/carddisp.pl?gene=PGR&keywords=estrogen,receptor.

53.

Greer

J. B.

Modugno

Allen

G. O.

Ness

R. B.

. 2005. “Short-term Oral Contraceptive Use and the Risk of Epithelial Ovarian Cancer.” American Journal of Epidemiology 162, no. 1: 66–72.

54.

Haile

R. W.

Thomas

D. C.

McGuire

Felberg

John

E. M.

Milne

R. L.

Hopper

J. L.

. 2006. “BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer before Age 50.” Cancer Epidemiology, Biomarkers & Prevention 15:1863–70.

55.

Hannaford

P. C.

Selvaraj

Elliott

A. M.

Angus

Iversen

Lee

A. J.

. 2007. “Cancer Risk among Users of Oral Contraceptives: Cohort Data from the Royal College of General Practitioner’s Oral Contraception Study.” British Medical Journal 335:651.

56.

Heikkinen

Koskenvuo

Malila

Sarkeala

Pukkala

Pitkäniemi

. 2016. “Use of Exogenous Hormones and the Risk of Breast Cancer: Results from Self-reported Survey Data with Validity Assessment.” Cancer Causes & Control 27:249–58.

57.

Huang

Gao

Wen

Zheng

Shu

X. O.

Beeghly-Fadiel

. 2015. “Contraceptive Methods and Ovarian Cancer Risk among Chinese Women: A Report from the Shanghai Women’s Health Study.” International Journal of Cancer 137, no. 3: 607–14. doi: 10.1002/ijc.29412.

58.

Hunter

D. J.

Colditz

G. A.

Hankinson

S. E.

Malspeis

Spiegelman

Chen

Stampfer

M. J.

Willett

W. C.

. 2010. “Oral Contraceptive Use and Breast Cancer: A Prospective Study of Young Women.” Cancer Epidemiology, Biomarkers & Prevention 19:2496–502.

59.

Hüsing

Dossus

Ferrari

Tjønneland

Hansen

Fagherazzi

Baglietto

. 2016. “An Epidemiological Model for Prediction of Endometrial Cancer Risk in Europe.” European Journal of Epidemiology 31:51–60.

60.

Ichida

Kataoka

Tsushima

Taguchi

. 2015. “No Increase in Breast Cancer Risk in Japanese Women Taking Oral Contraceptives: A Case-control Study Investigating Reproductive, Menstrual and Familial Risk Factors for Breast Cancer.” Asian Pacific Journal of Cancer Prevention 16:3685–90.

61.

IARC (International Agency for Research on Cancer). 2007. Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 91. http://monographs.iarc.fr/ENG/Monographs/vol91/mono91.pdf.

62.

IARC (International Agency for Research on Cancer). 2012. Combined Estrogen-Progestogen Contraceptives. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 100A: 283–318. http://monographs.iarc.fr/ENG/Monographs/vol100A/mono100A-19.pdf.

63.

International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby

Beral

Berrington de González

Colin

Franceschi

Goodhill

. 2007. “Cervical Cancer and Hormonal Contraceptives: Collaborative Reanalysis of Individual Data for 16,573 Women with Cervical Cancer and 35,509 Women without Cervical Cancer from 24 Epidemiological Studies.” Lancet 370:1609–21.

64.

Iodice

Barile

Rotmensz

Feroce

Bonanni

Radice

Bernard

Maisonneuve

Gandini

. 2010. “Oral Contraceptive Use and Breast or Ovarian Cancer Risk in BRCA1/2 Carriers: A Meta-analysis.” European Journal of Cancer Care 46, no. 12: 2275–84. doi: 10.1016/j.ejca.2010.04.018.

65.

Jernström

Loman

Johannsson

O. T.

Borg

Olsson

. 2005. “Impact of Teenage Oral Contraceptive Use in a Population-based Series of Early-onset Breast Cancer Cases Who Have Undergone BRCA Mutation Testing.” European Journal of Cancer Care 41:2312–20.

66.

Kabat

G. C.

Miller

A. B.

Rohan

T. E.

. 2008. “Oral Contraceptive Use, Hormone Replacement Therapy, Reproductive History and Risk of Colorectal Cancer in Women.” International Journal of Cancer 122:643–46.

67.

Kabat

G. C.

Silvera

S. A.

Miller

A. B.

Rohan

T. E.

. 2007. “A Cohort Study of Reproductive and Hormonal Factors and Renal Cell Cancer Risk in Women.” British Journal of Cancer 96:845–49.

68.

Karami

Daugherty

S. E.

Schonfeld

S. J.

Park

Hollenbeck

A. R.

Grubb

R. L.

III Hofmann

J. N.

Chow

W. H.

Purdue

M. P.

. 2013. “Reproductive Factors and Kidney Cancer Risk in 2 US Cohort Studies, 1993–2010.” American Journal of Epidemiology 177:1368–77.

69.

Kotsopoulos

Lubinski

Gronwald

Cybulski

Demsky

Neuhausen

S. L.

Kim-Sing

. 2015. “Factors Influencing Ovulation and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers.” International Journal of Cancer 137, no. 5: 1136–46. doi: 10.1002/ijc.29386.

70.

Kotsopoulos

Lubinski

Moller

Lynch

H. T.

Singer

C. F.

Eng

Neuhausen

S. L.

. 2014. “Timing of Oral Contraceptive Use and the Risk of Breast Cancer in BRCA1 Mutation Carriers.” Breast Cancer Research and Treatment 143:579–86.

71.

Kurta

M. L.

Moysich

K. B.

Weissfeld

J. L.

Youk

A. O.

Bunker

C. H.

Edwards

R. P.

Modugno

Ness

R. B.

Diergaarde

. 2012. “Use of Fertility Drugs and Risk of Ovarian Cancer: Results from a U.S.-based Case-control Study.” Cancer Epidemiology, Biomarkers & Prevention 21, no. 8: 1282–92. doi: 10.1158/1055-9965.EPI-12-0426.

72.

D. C.

Kubo

Fujino

Sokal

D. C.

Vach

T. H.

Pham

T. M.

Matsuda

. 2012. “Reproductive Factors in Relation to Ovarian Cancer: A Case-control Study in Northern Vietnam.” Contraception 86, no. 5: 494–99. doi: 10.1016/j.contraception.2012.02.019.

73.

N. D.

Leung

Brooks-Wilson

Gallagher

R. P.

Swenerton

K. D.

Demers

P. A.

Cook

L. S.

. 2014. “Occupational Exposure and Ovarian Cancer Risk.” Cancer Causes & Control 25, no. 7: 829–41. doi: 10.1007/s10552-014-0384-4.

74.

Lee

McKean-Cowdin

Van Den Berg

Bernstein

Henderson

B. E.

Ursin

. 2008. “Effect of Reproductive Factors and Oral Contraceptives on Breast Cancer Risk in BRCA1/2 Mutation Carriers and Noncarriers: Results from a Population-based Study.” Cancer Epidemiology, Biomarkers & Prevention 17:3170–78.

75.

Lee

J. E.

Hankinson

S. E.

Cho

. 2009. “Reproductive Factors and Risk of Renal Cell Cancer: The Nurses’ Health Study.” American Journal of Epidemiology 169:1243–50.

76.

Leslie

H. H.

Karasek

D. A.

Harris

L. F.

Chang

Abdulrahim

Maloba

Huchko

M. J.

. 2014. “Cervical Cancer Precursors and Hormonal Contraceptive Use in HIV-positive Women: Application of a Causal Model and Semi-parametric Estimation Methods.” PLoS One 9:e101090.

77.

Leslie

K. K.

Espey

. 2005. “Oral Contraceptives and Skin Cancer: Is there a Link?” American Journal of Clinical Dermatology 6:349–55.

78.

C. I.

Beaber

E. F.

Tang

M. T.

Porter

P. L.

Daling

J. R.

Malone

K. E.

. 2012. “Effect of Depo-medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age.” Cancer Research 72:2028–35.

79.

Lin

Zhang

S. M.

Cook

N. R.

Manson

J. E.

Buring

J. E.

Lee

I. M.

. 2007. “Oral Contraceptives, Reproductive Factors, and Risk of Colorectal Cancer among Women in a Prospective Cohort Study.” American Journal of Epidemiology 165:794–801.

80.

Long

M. D.

Martin

C. F.

Galanko

J. A.

Sandler

R. S.

. 2010. “Hormone Replacement Therapy, Oral Contraceptive Use, and Distal Large Bowel Cancer: A Population-based Case-control Study.” American Journal of Gastroenterology 105:1843–50.

81.

Luan

N. N.

Gong

T. T.

Wang

Y. L.

Lin

Q. J.

. 2015. “Nonlinear Reduction in Risk for Colorectal Cancer by Oral Contraceptive Use: A Meta-analysis of Epidemiological Studies.” Cancer Causes & Control 26:65–78.

82.

Lumachi

Frigo

A. C.

Basso

Tombolan

Ermani

. 2010. “Estrogen Therapy and Risk of Breast Cancer in Postmenopausal Women: A Case-control Study and Results of a Multivariate Analysis.” Menopause 17:524–28.

83.

Lund

Bakken

Dumeaux

Andersen

Kumle

. 2007. “Hormone Replacement Therapy and Breast Cancer in Former Users of Oral Contraceptives—The Norwegian Women and Cancer Study.” International Journal of Cancer 121:645–48.

84.

Lurie

Wilkens

L. R.

Thompson

P. J.

McDuffie

K. E.

Carney

M. E.

Terada

K. Y.

Goodman

M. T.

. 2008. “Combined Oral Contraceptive Use and Epithelial Ovarian Cancer Risk: Time-related Effects.” Epidemiology 19, no. 2: 237–43. doi: 10.1097/EDE.0b013e31816334c5.

85.

Bernstein

Ross

R. K.

Ursin

. 2006. “Hormone-related Risk Factors for Breast Cancer in Women Under Age 50 Years by Estrogen and Progesterone Receptor Status: Results from a Case-control and a Case-case Comparison.” Breast Cancer Research 8:R39.

86.

Wang

Sullivan-Halley

Weiss

Marchbanks

P. A.

Spirtas

Ursin

. 2010. “Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women’s Contraceptive and Reproductive Experiences Study.” Cancer Research 70:575–87.

87.

Matos

Moutinho

Pinto

Medeiros

. 2005. “The Influence of Smoking and Other Cofactors on the Time to Onset to Cervical Cancer in a Southern European Population.” European Journal of Cancer Prevention 14:485–91.

88.

Maxwell

G. L.

Schildkraut

J. M.

Calingaert

Risinger

J. I.

Dainty

Marchbanks

P. A.

Berchuck

Barrett

J. C.

Rodriguez

G. C.

. 2006. “Progestin and Estrogen Potency of Combination Oral Contraceptives and Endometrial Cancer Risk.” Gynecologic Oncology 103:535–40.

89.

McFarlane-Anderson

Bazuaye

P. E.

Jackson

M. D.

Smikle

Fletcher

H. M.

. 2008. “Cervical Dysplasia and Cancer and the Use of Hormonal Contraceptives in Jamaican Women.” BMC Womens Health 8:9.

90.

McGlynn

K. A.

Sahasrabuddhe

V. V.

Campbell

P. T.

Graubard

B. I.

Chen

Schwartz

L. M.

Petrick

J. L.

. 2015. “Reproductive Factors, Exogenous Hormone Use and Risk of Hepatocellular Carcinoma among US Women: Results from the Liver Cancer Pooling Project.” British Journal of Cancer 112:1266–72.

91.

McLaughlin

J. R.

Risch

H. A.

Lubinski

Moller

Ghadirian

Lynch

Karlan

. 2007. “Reproductive Risk Factors for Ovarian Cancer in Carriers of BRCA1 or BRCA2 Mutations: A Case-control Study.” Lancet Oncology 8, no. 1: 26–34.

92.

Meinhold

C. L.

Berrington de González

Bowman

E. D.

Brenner

A. V.

Jones

R. T.

Lacey

J. V.

Jr. Loffredo

C. A.

. 2011. “Reproductive and Hormonal Factors and the Risk of Nonsmall Cell Lung Cancer.” International Journal of Cancer 128:1404–13.

93.

Merritt

M. A.

Riboli

Murphy

Kadi

Tjønneland

Olsen

Overvad

. 2015. “Reproductive Factors and Risk of Mortality in the European Prospective Investigation into Cancer and Nutrition; A Cohort Study.” BMC Medicine 13:252.

94.

Milne

R. L.

Knight

J. A.

John

E. M.

Dite

G. S.

Balbuena

Ziogas

Andrulis

I. L.

. 2005. “Oral Contraceptive Use and Risk of Early-onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations.” Cancer Epidemiology, Biomarkers & Prevention 14:350–56.

95.

Moorman

P. G.

Calingaert

Palmieri

R. T.

Iversen

E. S.

Bentley

R. C.

Halabi

Berchuck

Schildkraut

J. M.

. 2008. “Hormonal Risk Factors for Ovarian Cancer in Premenopausal and Postmenopausal Women.” American Journal of Epidemiology 167, no. 9: 1059–69. doi: 10.1093/aje/kwn006.

96.

Moorman

P. G.

Havrilesky

L. J.

Gierisch

J. M.

Coeytaux

R. R.

Lowery

W. J.

Peragallo Urrutia

Dinan

. 2013. “Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer among High-risk Women: A Systematic Review and Meta-analysis.” Journal of Clinical Oncology 31, no. 33: 4188–98. doi: 10.1200/JCO.2013.48.9021.

97.

Moorman

P. G.

Palmieri

R. T.

Akushevich

Berchuck

Schildkraut

J. M.

. 2009. “Ovarian Cancer Risk Factors in African-American and White Women.” American Journal of Epidemiology 170, no. 5: 598–606. doi:10.1093/aje/kwp176.

98.

Mørch

L. S.

Skovlund

C. W.

Hannaford

P. C.

Iversen

Fielding

Lidegaard

Ø.

. 2017. “Contemporary Hormonal Contraception and the Risk of Breast Cancer.” New England Journal of Medicine 377:2228–39.

99.

Navarro Silvera

S. A.

Miller

A. B.

Rohan

T. E.

. 2005. “Hormonal and Reproductive Factors and Pancreatic Cancer Risk: A Prospective Cohort Study.” Pancreas 30:369–74.

100.

Ness

R. B.

Dodge

R. C.

Edwards

R. P.

Baker

J. A.

Moysich

K. B.

. 2011. “Contraception Methods, Beyond Oral Contraceptives and Tubal Ligation, and Risk of Ovarian Cancer.” Annals of Epidemiology 21, no. 3: 188–96. doi: 10.1016/j.annepidem.2010.10.002.

101.

Okamura

Tsubono

Ito

Niikura

Takano

Nagase

Yoshinaga

. 2006. “Lactation and Risk of Endometrial Cancer in Japan: A Case-control Study.” Tohoku Journal of Experimental Medicine 208:109–15.

102.

Ozmen

Ozcinar

Karanlik

Cabioglu

Tukenmez

Disci

Ozmen

. 2009. “Breast Cancer Risk Factors in Turkish Women—A University Hospital Based Nested Case Control Study.” World Journal of Surgical Oncology 7:37.

103.

Pagano

Gauvreau

. 2000. Principles of Biostatistics, 2nd ed. Belmont, CA: Brooks/Cole.

104.

Parshall

M. B.

2013. “Unpacking the 2 × 2 Table.” Heart & Lung 42:221–26.

105.

Patel

M. I.

Wang

Kapphahn

Desai

Chlebowski

R. T.

Simon

M. S.

Bird

C. E.

. 2016. “Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results from the Women’s Health Initiative.” Journal of Clinical Oncology 34:360–68.

106.

Paul VI

Pope

. 1968. Humanae Vitae. http://w2.vatican.va/content/paul-vi/en/encyclicals/documents/hf_p-vi_enc_25071968_humanae-vitae.html.

107.

Pearce

C. L.

Rossing

M. A.

Lee

A. W.

Ness

R. B.

Webb

P. M.

Chenevix-Trench

Jordan

S. M.

. 2013. “Combined and Interactive Effects of Environmental and GWAS-identified Risk Factors in Ovarian Cancer.” Cancer Epidemiology, Biomarkers & Prevention 22, no. 5: 880–90.

108.

Pelucchi

Galeone

Talamini

Bosetti

Montella

Negri

Franceschi

La Vecchia

. 2007. “Lifetime Ovulatory Cycles and Ovarian Cancer Risk in 2 Italian Case-control Studies.” American Journal of Obstetrics and Gynecology 196, no. 1: 83.e1–7.

109.

Perri

Lifshitz

Sadetzki

Oberman

Meirow

Ben-Baruch

Friedman

Korach

. 2015. “Fertility Treatments and Invasive Epithelial Ovarian Cancer Risk in Jewish Israeli BRCA1 or BRCA2 Mutation Carriers.” Fertility and Sterility 103, no. 5: 1305–12. doi: 10.1016/j.fertnstert.2015.02.011.

110.

Pesatori

A. C.

Carugno

Consonni

Caporaso

N. E.

Wacholder

Tucker

Landi

M. T.

. 2013. “Reproductive and Hormonal Factors and the Risk of Lung Cancer: The EAGLE Study.” International Journal of Cancer 132:2630–39.

111.

Pesatori

A. C.

Carugno

Consonni

Hung

R. J.

Papadoupolos

Landi

M. T.

Brenner

. 2013. “Hormone Use and Risk for Lung Cancer: A Pooled Analysis from the International Lung Cancer Consortium (ILCCO).” British Journal of Cancer 109:1954–64.

112.

Pfeiffer

R. M.

Park

Kreimer

A. R.

Lacey

J. V.

Jr. Pee

Greenlee

R. T.

Buys

S. S.

. 2013. “Risk Prediction for Breast, Endometrial, and Ovarian Cancer in White Women Aged 50 y or Older: Derivation and Validation from Population-based Cohort Studies.” PLoS Medicine 10, no. 7: e1001492. doi: 10.1371/journal.pmed.1001492.

113.

Phipps

A. I.

Chlebowski

R. T.

Prentice

McTiernan

Wactawski-Wende

Kuller

L. H.

Adams-Campbell

L. L.

. 2011. “Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-negative Breast Cancer.” Journal of the National Cancer Institute 103:470–77.

114.

Polesel

Serraino

Zucchetto

Lucenteforte

Dal Maso

Levi

Negri

. 2009. “Cigarette Smoking and Endometrial Cancer Risk: The Modifying Effect of Obesity.” European Journal of Cancer Prevention 18:476–81.

115.

Poole

E. M.

Merritt

M. A.

Jordan

S. J.

Yang

H. P.

Hankinson

S. E.

Park

Rosner

. 2013. “Hormonal and Reproductive Risk Factors for Epithelial Ovarian Cancer by Tumor Aggressiveness.” Cancer Epidemiology, Biomarkers & Prevention 22, no. 3: 429–37. doi: 10.1158/1055-9965.EPI-12-1183-T.

116.

Poosari

Promthet

Kamsa-ard

Suwanrungruang

Longkul

Wiangnon

. 2014. “Hormonal Contraceptive Use and Breast Cancer in Thai Women.” Journal of Epidemiology 24:216–20.

117.

Rosenberg

Boggs

D. A.

Wise

L. A.

Adams-Campbell

L. L.

Palmer

J. R.

. 2010. “Oral Contraceptive Use and Estrogen/Progesterone Receptor-negative Breast Cancer among African American Women.” Cancer Epidemiology, Biomarkers & Prevention 19:2073–79.

118.

Rosenberg

Zhang

Coogan

P. F.

Strom

B. L.

Palmer

J. R.

. 2008. “A Case-control Study of Oral Contraceptive Use and Incident Breast Cancer. American Journal of Epidemiology 169:473–79.

119.

Rota

Rumi

Bagnardi

Dal Maso

Zucchetto

Levi

La Vecchia

Tavani

. 2016. “Modelling Body Mass Index and Endometrial Cancer Risk in a Pooled-analysis of Three Case-control Studies.” British Journal of Obstetrics and Gynaecology 123:285–92.

120.

Roura

Travier

Waterboer

de Sanjosé

Bosch

F. X.

Pawlita

Pala

. 2016. “The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort.” PLoS One 11:e0147029.

121.

Rudolph

Toth

Hoffmeister

Roth

Herpel

Schirmacher

Brenner

Chang-Claude

2013. “Colorectal Cancer Risk Associated with Hormone Use Varies by Expression of Estrogen Receptor-α.” Cancer Research 73:3306–15.

122.

Samson

M. E.

Adams

S. A.

Mulatya

C. M.

Zhang

Bennett

C. L.

Hebert

Steck

S. E.

. 2017. “Types of Oral Contraceptives and Breast Cancer Survival among Women Enrolled in Medicaid: A Competing-risk Model.” Maturitas 95:42–49.

123.

Schonfeld

S. J.

Hartge

Pfeiffer

R. M.

Freedman

D. M.

Greenlee

R. T.

Linet

M. S.

Park

Schairer

Visvanathan

Lacey

J. V.

Jr . 2013. “An Aggregated Analysis of Hormonal Factors and Endometrial Cancer Risk by Parity.” Cancer 119:1393–401.

124.

Schonfeld

S. J.

Ron

Kitahara

C. M.

Brenner

Park

Sigurdson

A. J.

Schatzkin

de González

A. B.

. 2011. “Hormonal and Reproductive Factors and Risk of Postmenopausal Thyroid Cancer in the NIH-AARP Diet and Health Study.” Cancer Epidemiology 35:e85–90.

125.

Schwartz

A. G.

Ray

R. M.

Cote

M. L.

Abrams

Sokol

R. J.

Hendrix

S. L.

Chen

. 2015. “Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women’s Health Initiative Studies.” Journal of Thoracic Oncology 10:1004–13.

126.

Segev

Rosen

Lubinski

Gronwald

Lynch

H. T.

Moller

Kim-Sing

. 2015. “Risk Factors for Endometrial Cancer among Women with a BRCA1 or BRCA2 Mutation: A Case Control Study. Familial Cancer 14:383–91.

127.

Setiawan

V. W.

Monroe

K. R.

Goodman

M. T.

Kolonel

L. N.

Pike

M. C.

Henderson

B. E.

. 2007. “Alcohol Consumption and Endometrial Cancer Risk: The Multiethnic Cohort.” International Journal of Cancer 122:634–38.

128.

Silvera

S. A.

Miller

A. B.

Rohan

T. E.

. 2005. “Oral Contraceptive Use and Risk of Breast Cancer among Women with a Family History of Breast Cancer: A Prospective Cohort Study.” Cancer Causes & Control 16:1059–63.

129.

Soegaard

Jensen

Høgdall

Christensen

Høgdall

Blaakaer

Kjaer

S. K.

. 2007. “Different Risk Factor Profiles for Mucinous and Nonmucinous Ovarian Cancer: Results from the Danish MALOVA Study.” Cancer Epidemiology, Biomarkers & Prevention 16, no. 6: 1160–66.

130.

Soini

Hurskainen

Grénman

Mäenpää

Paavonen

Joensuu

Pukkala

. 2016. “Levonorgestrel-releasing Intrauterine System and the Risk of Breast Cancer: A Nationwide Cohort Study.” Acta Oncologica 55:188–92.

131.

Soini

Hurskainen

Grénman

Mäenpää

Paavonen

Pukkala

. 2014. “Cancer Risk in Women Using the Levonorgestrel-releasing Intrauterine System in Finland.” Obstetrics & Gynecology 124 (2 Pt 1): 292–99. doi: 10.1097/AOG.0000000000000356.

132.

Spruance

Reid

J. E.

Grace

Samore

. 2004. “Hazard Ratio in Clinical Trials.” Antimicrobial Agents and Chemotherapy 48:2787–92.

133.

Sweeney

Giuliano

A. R.

Baumgartner

K. B.

Byers

Herrick

J. S.

Edwards

S. L.

Slattery

M. L.

. 2007. “Oral, Injected and Implanted Contraceptives and Breast Cancer Risk among U.S. Hispanic and Non-Hispanic White Women. International Journal of Cancer 121:2517–23.

134.

Tan

H. S.

Tan

M. H.

Chow

K. Y.

Chay

W. Y.

Lim

W. Y.

. 2015. “Reproductive Factors and Lung Cancer Risk among Women in the Singapore Breast Cancer Screening Project.” Lung Cancer 90:499–508.

135.

Tang

Yuan

Wang

. 2015. “Relationship between Female Hormonal and Menstrual Factors and Pancreatic Cancer: A Meta-analysis of Observational Studies.” Medicine (Baltimore) 94:e177.

136.

Tao

M. H.

W. H.

Zheng

Zhang

Z. F.

Gao

Y. T.

Ruan

Z. X.

Cheng

J. R.

Gao

Xiang

Y. B.

Shu

X. O.

. 2006. “Oral Contraceptive and IUD Use and Endometrial Cancer: A Population-based Case-control Study in Shanghai, China.” International Journal of Cancer 119:2142–47.

137.

Tehranian

Shobeiri

Pour

F. H.

Hagizadeh

. 2010. “Breast Cancer Risk Assessments Comparing Gail and CARE Models in African-American Women.” Breast Journal 15 (Suppl. 1): S72–75.

138.

Terada

K. Y.

Ahn

H. J.

Kessel

. 2016. “Differences in Risk for Type 1 and Type 2 Ovarian Cancer in a Large Cancer Screening Trial.” Journal of Gynecologic Oncology 27, no. 3: e25. doi: 10.3802/jgo.2016.27.e25.

139.

Teras

L. R.

Patel

A. V.

Rodriguez

Thun

M. J.

Calle

E. E.

. 2005. “Parity, Other Reproductive Factors, and Risk of Pancreatic Cancer Mortality in a Large Cohort of U.S. Women (United States).” Cancer Causes & Control 16:1035–40.

140.

Thorbjarnardottir

Olafsdottir

E. J.

Valdimarsdottir

U. A.

Olafsson

Tryggvadottir

. 2014. “Oral Contraceptives, Hormone Replacement Therapy and Breast Cancer Risk: A Cohort Study of 16 928 Women 48 Years and Older.” Acta Oncologica 53:752–58.

141.

Torres

M. L.

Weaver

A. L.

Kumar

Uccella

Famuyide

A. O.

Cliby

W. A.

Dowdy

S. C.

Gostout

B. S.

Mariani

. 2012. “Risk Factors for Developing Endometrial Cancer after Benign Endometrial Sampling.” Obstetrics & Gynecology 120:998–1004.

142.

Trivers

K. F.

Gammon

M. D.

Abrahamson

P. E.

Lund

M. J.

Flagg

E. W.

Moorman

P. G.

Kaufman

J. S.

. 2007. “Oral Contraceptives and Survival in Breast Cancer Patients Aged 20 to 54 Years.” Cancer Epidemiology, Biomarkers & Prevention 16:1822–27.

143.

Truong

Orsi

Dubourdieu

Rougier

Hémon

Guénel

2005. “Role of Goiter and of Menstrual and Reproductive Factors in Thyroid Cancer: A Population-based Case-control Study in New Caledonia (South Pacific), A Very High Incidence Area.” American Journal of Epidemiology 161:1056–65.

144.

Tsilidis

K. K.

Allen

N. E.

Key

T. J.

Bakken

Lund

Berrino

Fournier

. 2010. “Oral Contraceptives, Reproductive History and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition.” British Journal of Cancer 103:1755–59.

145.

Tsilidis

K. K.

Allen

N. E.

Key

T. J.

Dossus

Lukanova

Bakken

Lund

. 2011. “Oral Contraceptive Use and Reproductive Factors and Risk of Ovarian Cancer in the European Prospective Investigation into Cancer and Nutrition.” British Journal of Cancer 105, no. 9: 1436–42. doi: 10.1038/bjc.2011.371.

146.

Tworoger

S. S.

Fairfield

K. M.

Colditz

G. A.

Rosner

B. A.

Hankinson

S. E.

. 2007. “Association of Oral Contraceptive Use, Other Contraceptive Methods, and Infertility with Ovarian Cancer Risk.” American Journal of Epidemiology 166, no. 8: 894–901.

147.

United Nations, Department of Economic and Social Affairs, Population Division. 2015. Trends in Contraceptive Use Worldwide 2015. New York: United Nations. http://www.un.org/en/development/desa/population/publications/pdf/family/trendsContraceptiveUse2015Report.pdf.

148.

Vaisy

Lotfinejad

Zhian

. 2014. “Risk of Cancer with Combined Oral Contraceptive Use among Iranian Women.” Asian Pacific Journal of Cancer Prevention 15:5517–22.

149.

Vanakankovit

Taneepanichskul

. 2008. “Effect of Oral Contraceptives on Risk of Cervical Cancer.” Journal of the Medical Association of Thailand 91:7–12.

150.

Veisy

Lotfinejad

Salehi

Zhian

. 2015. “Risk of Breast Cancer in Relation to Reproductive Factors in North-West of Iran, 2013–2014.” Asian Pacific Journal of Cancer Prevention 16:451–55.

151.

Veneroso

Siegel

Levine

P. H.

. 2008. “Early Age at First Childbirth Associated with Advanced Tumor Grade in Breast Cancer.” Cancer Detection and Prevention 32:215–23.

152.

Vessey

Painter

2006. “Oral Contraceptive Use and Cancer. Findings in a Large Cohort Study, 1968–2004.” British Journal of Cancer 95, no. 3: 385–89.

153.

Vessey

Yeates

. 2013. “Oral Contraceptive Use and Cancer: Final Report from the Oxford-Family Planning Association Contraceptive Study.” Contraception 88, no. 6: 678–83. doi: 10.1016/j.contraception.2013.08.008.

154.

von Elm

Altman

D. G.

Egger

Pocock

S. J.

Gøtzsche

P. C.

Vandenbroucke

J. P.

; STROBE Initiative. 2007. “The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies.” PLoS Medicine 4: 1623–27 (e296). doi: 10.1371/journal.pmed. 0040296.

155.

Wang

Butler

L. M.

A. H.

Koh

W. P.

Jin

Wang

Yuan

J. M.

. 2016. “Reproductive Factors, Hormone Use and Gastric Cancer Risk: The Singapore Chinese Health Study.” International Journal of Cancer 138:2837–45.

156.

Wang

Qiu

. 2015. “Increased Risk of Papillary Thyroid Cancer Related to Hormonal Factors in Women.” Tumour Biology 36:5127–32.

157.

Weiss

J. M.

Saltzman

B. S.

Doherty

J. A.

Voigt

L. F.

Chen

Beresford

S. A.

Hill

D. A.

Weiss

N. S.

. 2006. “Risk Factors for the Incidence of Endometrial Cancer According to the Aggressiveness of Disease.” American Journal of Epidemiology 164:56–62.

158.

Wernli

K. J.

Wang

Zheng

Potter

J. D.

Newcomb

P. A.

. 2009. “The Relationship between Gravidity and Parity and Colorectal Cancer Risk.” Journal of Women’s Health (Larchmt) 18:995–1001.

159.

Wilailak

Vipupinyo

Suraseranivong

Chotivanich

Kietpeerakool

Tanapat

Therasakvichya

. 2012. “Depot Medroxyprogesterone Acetate and Epithelial Ovarian Cancer: A Multicentre Case-control Study.” British Journal of Obstetrics and Gynaecology 119, no. 6: 672–77. doi: 10.1111/j.1471-0528.2012.03298.x.

160.

Wilson

J. C.

O’Rorke

M. A.

Cooper

J. A.

Murray

L. J.

Hughes

C. M.

Gormley

G. J.

Anderson

L. A.

. 2013. “Non-steroidal Anti-inflammatory Drug Use and Cervical Cancer Risk: A Case-control Study Using the Clinical Practice Research Datalink.” Cancer Epidemiology 37:897–904.

161.

Wolpert

B. J.

Amr

Ezzat

Saleh

Gouda

Loay

Hifnawy

. 2010. “Estrogen Exposure and Bladder Cancer Risk in Egyptian Women.” Maturitas 67:353–57.

162.

Zhu

. 2015. “Linear Reduction in Thyroid Cancer Risk by Oral Contraceptive Use: A Dose-response Meta-analysis of Prospective Cohort Studies.” Human Reproduction 30:2234–40.

163.

Yang

H. P.

Trabert

Murphy

M. A.

Sherman

M. E.

Sampson

J. N.

Brinton

L. A.

Hartge

Hollenbeck

Park

Wentzensen

. 2012. “Ovarian Cancer Risk Factors by Histologic Subtypes in the NIH-AARP Diet and Health Study.” International Journal of Cancer 131, no. 4: 938–48. doi: 10.1002/ijc.26469.

164.

Zervoudakis

Strickler

H. D.

Park

Xue

Hollenbeck

Schatzkin

Gunter

M. J.

. 2011. “Reproductive History and Risk of Colorectal Cancer in Postmenopausal Women.” Journal of the National Cancer Institute 103:826–34.

165.

Zhang

Coogan

P. F.

Palmer

J. R.

Strom

B. L.

Rosenberg

. 2010. “A Case-control Study of Reproductive Factors, Female Hormone Use, and Risk of Pancreatic Cancer.” Cancer Causes & Control 21:473–78.

166.

Zhu

Lei

Feng

Wang

. 2012. “Oral Contraceptive Use and Risk of Breast Cancer: A Meta-analysis of Prospective Cohort Studies.” European Journal of Contraception and Reproductive Health Care 17:402–14.

167.

Zucchetto

Serraino

Polesel

Negri

De Paoli

Dal Maso

Montella

La Vecchia

Franceschi

Talamini

. 2009. “Hormone-related Factors and Gynecological Conditions in Relation to Endometrial Cancer Risk.” European Journal of Cancer Prevention 18:316–21.

168.

Zucchetto

Talamini

Dal Maso

Negri

Polesel

Ramazzotti

Montella

. 2008. “Reproductive, Menstrual, and Other Hormone-related Factors and Risk of Renal Cell Cancer.” International Journal of Cancer 123:2213–16.